Early Cancer Detection via Liquid Biopsy
Meridian Bio · Boston, MA
"A simple blood test to detect 12 cancers before symptoms appear"
About Meridian Bio
More than 60% of cancer deaths are caused by cancers that lack recommended early screening tests. Meridian Bio is changing that.
Our MCED test analyzes cell-free DNA methylation patterns in a standard blood draw to detect 12 of the most deadly cancers — including pancreatic, ovarian, and esophageal — at Stage I or II, when survival rates exceed 85%.
We've completed a 1,200-patient validation study with 89% sensitivity and 98.5% specificity. We are currently enrolling for a pivotal clinical trial (n=8,000) and expect to submit our PMA application to the FDA in Q3 2026.
Meridian Bio has raised $12M in institutional venture capital to date. This Reg CF raise offers the public an opportunity to participate alongside our institutional investors on identical economic terms via SAFE notes.
Use of Funds
Funding Progress
37% funded
Not FDIC insured · Investing involves risk · Disclosures